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Different mutations in the COL4A5 collagen gene in two patients with
different features of Alport syndrome. Alport syndrome is a hereditary
renal disease in which progressive renal failure is often accompanied by
sensorineural deafness and ocular abnormalities. Recently, mutations
were detected in the type IV collagen a5 chain gene in Alport syndrome
patients. We searched for mutations in this gene in 18 unrelated
patients, and in two patients abnormalities were detected. In the gene of
patient BB we identified a complex deletion, which included the exons
encoding the non-collagenous domain and part of the collagenous
region. This patient showed early onset nephritis (end-stage renal
disease at 17 years) with deafness. Within a year after receiving a
kidney from an unrelated donor, he developed an antiglomerular
basement membrane nephritis. In patient WJ a point-mutation was
detected, changing a tryptophane into a serine in the non-collagenous
domain. His clinical features are milder (renal failure at 33 years, no
hearing loss), and a recent renal allograft did not provoke anti-
glomerular basement membrane disease. These initial data suggest that
differences in the extent of disruption of the non-collagenous domain
may correlate with the severity and/or heterogeneity of Alport syn-
drome and with the development of nephritis in renal allografts.
Alport syndrome (AS) is a progressive hereditary glomerulo-
nephritis with a heterogeneous clinical picture. Patients can be
classified by their age at end-stage renal disease (ESRD) and the
presence of accompanying features, such as hearing loss, ocular
malformations, macrothrombocytopenia and leiomyomatosis of
the esophagus [1]. Typical ultrastructural anomalies of the
glomerular basement membrane (GBM) include characteristic
lesions of the lamina densa. The clinical heterogeneity of AS
may reflect the involvement of different genes, because
X-linked dominant, autosomal dominant and autosomal reces-
sive modes of inheritance have been reported for AS [2].
However, the vast majority of AS pedigrees published thus far
show X-linked dominant inheritance [1, 3—51. Some trans-
planted male patients develop a post-transplant anti-GBM ne-
phritis, leading to irreversible graft failure [6]. In 11 out of 13
cases reported [6], nephritis appeared within nine months after
transplantation. Identification of patients predisposed to this
anti-GBM disease has not yet proven possible.
Recently, the cloning of the basement membrane type IV aS
collagen chain (COL4A5) gene has been reported [7]. Assign-
ment of this gene to the region on the long arm of the
X-chromosome, where the AS gene must be located, together
with the almost exclusive location of the gene product in the
GBM, made the involvement of the COL4A5 gene in AS very
likely. This was confirmed by the identification of mutations in
the COL4A5 gene in 3 out of 18 AS kindreds [8, 9] and 3 out of
38 in another study [10].
We searched for mutations in the COL4A5 gene in a group of
18 AS patients. First, we have screened Southern blots from the
genomic DNAs of our patients for major gene rearrangements.
From published data [8—101 it seemed likely that major gene
rearrangements were only a minority of the mutations involved.
Therefore, we also initiated a search for point mutations. A
combination of in vitro amplification of the exons coding for the
NC-domain with a search for single stranded-DNA conforma-
tion polymorphisms (SSCP) [11, 121 was applied. The confor-
mation of denatured, single stranded DNA is sequence depen-
dent and determines the electrophoretic mobility of the DNA
molecule. Most mutations alter the conformation of a DNA
fragment and will result in mobility shifts on non-denaturing
polyacrylamide gels. In our group of 18 AS patients, we
detected two patients with a mutation in the 3'-end of the
COL4A5 gene. Both the mutations and the clinical picture differ
between these patients, which indicates that analysis at the
gene level may become an indicator of prognosis for this
disease.
Methods
Patients
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Since the age of 10 patient BB was known to suffer from
proteinuria and hematuria. He developed sensorineural deaf-
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ness, Renal biopsies show typical abnormalities of the glomer-
ular basement membrane, consisting of irregular thickening and
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thinning, together with a multi-lamellated aspect with in-
tramembranous granules on electronmicroscopy. The disorder
was progressive and at the age of 17 the patient reached
end-stage renal disease (ESRD). Transplantation with the kid-
ney of an unrelated donor was followed by rapidly progressive
antiglomerular basement membrane nephritis, leading to loss of
the transplant within a few days of seven months after grafting
[13]. His affected maternal grandfather died from renal failure at
the age of 26 years.
Patient WJ had suffered from a progressive loss of renal
function since the age of 27. Renal disease has been slowly
progressive with rapid deterioration of kidney function from the
age of 33. A renal biopsy showed similar abnormalities as were
observed in the first patient. At age of 35 the patient received a
cadaveric kidney transplant. This transplant has functioned
adequately for nine months. Examination by standard audio-
metry did not show hearing loss. The patient has a similarly
affected brother. The pedigrees of both patients are consistent
with X-linked inheritance with more severe disease in affected
males than in affected females.
Materials and methods
Chromosomal DNA was isolated from peripheral blood [141.
DNA (10 g) was digested with EcoRI, PstI and TaqI (Gibco,
BRL), resolved by agarose gel electrophoresis and immobilized
on Gene Screen p1USTM (Du Pont, NEN, Boston, Massachu-
setts, USA) by Southern blotting, according to standard proce-
dures [151. The COL4A5 cDNA probes pJZ4, pHTl4, pPL31,
pMD-6 and pPC-4b (Fig. 1; [71, Zhou et a!, unpublished
observations), which cover the entire cDNA, were 32P labeled
by random primer synthesis [16]. Prehybridization and hybrid-
ization were performed at 65°C in 0.5 M Na,HPO4INaH2PO4
(pH = 7.2)17% (wtlvol) SDS. Filters were washed three times
for five minutes and once for 30 minutes at 65°C in 40 mM
Na2HPO4INaH2PO4IO. 1% SDS. For autoradiography, filters
were exposed to Kodak X-ray films for one to four days at
—70°C.
COL4A5 exons 1-5 were amplified in vitro using the PCR
methodology [17]. Exon flanking primers (Pharmacia, Uppsala,
Sweden) were synthesized based on the sequence data of Zhou
et al [18]. The primer sequences are (F indicates the forward
primer, R the reverse primer):
exon 1: AS1F: 5'-GAT CTG ATT GTC TTA TTT CTT ATT-3'
AS1R: 5'-TAA AAC ACA AAA GGA ATT CYI'
CAA-3'
exon 2: AS2F: 5'-TTG CGG CAC ATT TTT CCT TGT CTF-3'
AS2R: 5'-GGA CCT GAA 'ITA AAG CTA TAA
GCA-3'
exon 3: AS3F: 5'-ATT ATG TTC CTT CTC CTT TTC CTI'-3'
AS3R: 5'-ATG ACA AAT GCA AGG AAG AGT
GTA-3'
exon 4: AS4F: 5'-CTT TAC TGT TrF CTC TCC AAA TCT-3'
AS4R: 5'-AAA AGT CAC AGC TAA ATC AAT
GCC-3'
exon 5: ASSF: 5'-TCT TGT ATA CTG ATT ATT TCG TGG-3'
AS5R: 5'-CAG TAG GAA ATT AGA TAT TGA
TTA-3'
Mutation scanning was performed according to the procedure
of Orita et al [11, 12]. Single strand DNA was electrophoresed
under non-denaturing conditions on a 5% polyacrylamide se-
quencing gel (with and without 10% glycerol) in the cold room
(4°C) at 5 watts for 20 hours or at 40 watts for three hours.
Autoradiographic exposure was overnight. Sequence analysis
of double-stranded PCR products was performed using the
sequencing kit of Pharmacia. Template DNA was generated
according to the method described by Casanova et al [19]. PCR
products of COL4A5 exon 4 were digested with BsrI (New
England Biolabs Inc., Beverly, Massachusetts USA) and ana-
lyzed on 4% agarose gels, stained with ethidium bromide.
Results
Southern blot analysis of DNAs of AS patients was per-
formed to screen for major gene rearrangements. In only one
case were structural alterations detected in the COL4A5 gene.
No hybridization signals were visible with the probes pMD-6
and pPC4-b in the DNA of patient BB (Fig. 2A). Most signifi-
cant was the absence of the entire NC-domain in the COL4A5
chain of this patient. His gene was not deleted completely,
because probe pPL3 I and pHTl4 showed hybridization with his
DNA, though many of the bands, which were visible in the
DNA of controls, were lacking (Fig. 2B,C). The data are
suggestive for the presence of two deletions in his gene. The 3'
part of the gene was completely absent, but pPL3 1 detected
EcoRI fragments of 2.6 kb (Fig. 2B) and 1.4 kb (not visible),
indicating that most likely the exons 16 or 17 to 20, which are
covered by the 5' part of this eDNA probe, were present.
However, probe pHTl4, which lay at the 5' side adjacent to
pPL3 1, also lacked a number of the bands, which were visible
in the DNA of control individuals (Fig. 2C). Because there was
no map available of the 5' end of the gene, it was unclear which
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Fig. 2. A. Southern blot analysis of EcoR! digested DNA of patient BB and his family with probes pMD-6 and pPC4-b. These probes hybridize
with COL4A5 exons 1-11 and detect EcoRI fragments of, respectively, 7.5 kb, 6.6 kb, 2.4 kb, 1.4kb and 2 overlapping fragments of 1.2 kb. The
DNA of patient BB (2218) does not show any hybridization. B. Southern blot analysis of EcoRI digested DNA of patient BB and 3 male controls
(C) with probe pPL3I. The DNA of the patient displays a normal 2.6kb fragment and ajunction fragment of 6.6 kb. C. Analysis of the same blot
as in 2B with probe pHT14. Five of the bands, which are visible in the DNA of controls are missing in the DNA of patient BB. However, four other
bands and two junction fragments (6.6 kb and 5.4 kb) are present.
of the exons were missing. Probe pPL3 1 detected one junction
fragment of 6.6 kb and probe pHT14 two junction fragments of
6.6 kb and 5.4 kb (Fig. 2B,C). These junction fragments were
also present in the DNA of the mother and sister of the patient,
who both displayed hematuria, and revealed carriership of the
same complex deletion. The junction fragments were absent in
the DNA of his healthy grandmother (not shown). Probe pJZ4,
covering the 5' part of the gene, gave a completely normal
picture (data not shown).
We screened the five exons coding for the NC-domain for
small mutations, using single-strand conformation polymor-
phism (SSCP) analysis ll, 12]. This method revealed the
presence of a mutation in exon 4 (numbered from the 3' end) in
patient WJ (Fig. 3). Compared to control samples, the mobility
of the amplified fragment was clearly altered. Direct sequencing
of the PCR products revealed a single base mutation in the
DNA of the patient, which was not present in the DNA of
controls (Fig. 4). His affected brother carried the same mutation
and his mother was heterozygous. The single base alteration led
to a substitution of a guanine for a cytosine, changing a
tryptophane codon into a serine codon. The single base muta-
tion also destroyed a BsrI restriction site, which facilitated
DNA studies in the family the patient. As shown in Figure 5,
the absence of the BsrI site co-segregated with AS. Besides the
father of patient, 50 healthy controls (25 males and 25 females)
were tested for the BsrI polymorphism. All normal controls
showed presence of the BsrI site. In the other 16 AS patients no
mutation has been detected so far.
Discussion
In two patients belonging to clinically different types of AS,
we have detected mutations in the 3' part of the COL4A5 gene.
For patient BB, two deletions in his COL4A5 gene led to the
absence of the normal NC-domain and part of the collagenous
region. This complex deletion is different from the ones re-
ported before [8, 10], and the gene product might either be a
shorter collagen chain or contain a nonsense stretch of amino
acids. Therefore, a relationship to dysfunctioning of the GBM
and the development of renal disease is quite obvious. The
second patient (WJ) shows only a single base alteration in the
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Fig. 4. Sequence analysis of exon 4 DNA of patient WJ, his affected brother, his mother and a male control. The G to C transversion in the
patients changes a Trp codon (TGG) into an Ser codon (TCG). The mother is heterozygous and displays both a G and a C at that site.
fourth exon of the NC-domain (counted from the 3' end). The stituted tryptophane residue is highly conserved at that position
expected effect of the amino acid substitution would be a mild in both halves of the NC-domain in all type IV collagens from
alteration of the hydrophobicity of the protein segment, with as Drosophila to humans [20—23]. Evolutionary conservation is a
yet unknown consequences for structure and function of the strong indication of functional relevance of amino acids. Sec-
protein. However, there are two lines of evidence that this base ondly, we tested both the family of patient WJ and a number of
substitution is very likely the causal mutation. First, the sub- controls. In the family we found co-segregation of the mutation
Fig. 3. SSCP analysis of cxv,, 4 in AS patients and controls. Exon
amplification product is visible for the deletion patient BB (lane 6).
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Fig. 5. BsrI digestion of exon 4 of patient WJ and his family. The PCR
product is 238 bp long. Digestion with BsrI generates two fragments of
128 and 110 bp in controls (fe., 3054). The mutation has destroyed the
BsrI site in the DNA of patients 3053 and 3060. Their mother (3052) and
sister (3061) are heterozygous.
with the phenotypic expression of the disease. In contrast, in 50
healthy controls (75 chromosomes) no mutation was found.
Therefore, we conclude that this mutation is not a neutral
polymorphism, although it still remains possible that other
mutations can exist within the remaining unscanned part of the
gene.
The two patients described here have different clinical fea-
tures. Early onset of ESRD and hearing loss was found in
patient BB, who carries a complex rearrangement in his
COL4A5 gene, leading to the absence of a large part of the
normal COL4AS chain. The course of the disease is less severe
in the second patient and no hearing loss is detectable. No
major rearrangements have been found in his COL4A5 gene.
The single base mutation affects the NC-domain, but the
consequences appear to be limited to the glomerulus. The
reason for this is not clear at present. The kidney might be more
sensitive to alterations of the COL4A5 chain, although tissue-
specific isoforms of the COL4A5 chain may exist. Further
studies of COL4A5 expression in different tissues will help to
solve these questions.
The complex deletion in the COL4AS gene of patient BB
includes the entire NC-domain and, since the patient lacks the
normal epitopes of the COL4A5 NC-domain, is probably one of
the factors involved in the development of anti-GBM nephritis
after kidney transplantation. The reactivity of the anti-GBM
antibodies of this patient was similar to Goodpasture antibodies
and a monoclonal antibody directed against the Goodpasture
antigen (MCA-P1) [131. A large deletion is only one of the
causes leading to the absence of the entire protein or part of it,
a variety of other, small mutations can have a similar effect. For
example, small deletions or insertions, which cause a shift of
the reading frame, will result in a nonsense protein, and point
mutations, which introduce premature stop codons or prevent
normal transcription, will lead to truncation or absence of the
protein. Our data suggest that AS patients who have one of
those mutations in their COL4A5 gene may be at risk for the
development of anti-GBM nephritis upon kidney transplanta-
tion. It is obvious that more data on mutations in the COL4AS
gene of patients with anti-GBM nephritis need to be collected to
estimate this risk properly.
Two mechanisms were hypothesized to explain the develop-
ment of anti-GBM nephritis in a subgroup of AS patients [241.
The first hypothesis assumes that all patients lack the immuno-
logical tolerance for the Alport antigen, but that the occurrence
of anti-GBM nephritis is dependent on the immunological
setting of the patient. The second hypothesis postulates a
subgroup of patients with specific mutations in their gene that
prevent the expression of certain epitopes of the protein. This
latter possibility is supported by our data. It is evident that the
nature of the mutations in the COL4A5 gene is only one of the
factors involved; other endogenous and exogenous factors
contribute as well to the provocation and severity of the
immune response, leading to anti-GBM nephritis [13, 24]. A
clear demonstration of the involvement of exogenous factors
forms a familial case of four male patients, who were all
transplanted, but of whom only two lost their allografts because
of anti-GBM nephritis [25].
The two mutations described here increase the total number
reported to eight, of which seven have been characterized in
detail. These mutations are all different, which helps to explain
the clinical heterogeneity of X-linked AS. The two deletion
patients (patient BB reported here and patient 197701 from
kindred EP [8]) both suffer from severe hearing loss, whereas
hearing loss is absent in our patient WJ. This corroborates the
suggestion of Barker et al [8] that severity of deafness is directly
correlated with the severity of the defect in COL4A5. A wide
variety of mutations implies that each AS kindred might carry a
different mutation in COL4A5 and that for each kindred a
specific mutation must be identified. For osteogenesis imper-
fecta (01) similar findings were reported [26]. More than 70
mutations have been identified in type I collagen genes as the
molecular cause of different forms of 01 and insight into the
relation between mutation and severity of the disease is grow-
ing. Still, the picture is far from complete and it is estimated [26]
that the generation of an initial mutation map of type I collagen
genes requires the analysis of the phenotypic effects of at least
200 mutations. The size of the COL4AS gene is similar to those
genes and the number of mutations needed for the establish-
ment of a proper correlation between mutations in COL4A5 and
AS phenotypes may be similar as well.
In conclusion, our data suggest that gross rearragements of
the 3' end of the COL4A5 gene will lead to clinically severe AS
with early onset nephritis and profound deafness. Mild muta-
tions on the other hand, like the missense mutation at the 3' end
of the gene in patient WJ, will lead to a less severe phenotype.
372/AP
JJ
3060 3053 3054 3052 3061
238 bp
128 bp
110 bp
LU
88 Smeets et al: COL4A5 mutations in Alport syndrome
Moreover, our finding of a large deletion of the 3' end of the
COL4A5 gene in a patient with a de novo anti-GBM nephritis
after transplantation implies that a similar correlation may exist
between the severity of disruption of the NC-domain and the
development of anti-GBM nephritis.
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